Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites

Vaccine

Volumn 20, Issue 13-14, 2002, Pages 1853-1861

  Kublin, James G ^a   Lowitt, Mark H ^b   Hamilton, Robert G ^c   Oliveira, Giane A ^d   Nardin, Elizabeth H ^d   Nussenzweig, Ruth S ^d   Schmeckpeper, Barbara J ^c   Diggs, Carter L ^e   Bodison, Sacared A ^f   Edelman, Robert ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^f UNIVERSITY OF MARYLAND   (United States)

Author keywords

Cutaneous delayed type hypersensitivity; Malaria vaccine; Phase I vaccine trial

Indexed keywords

ANTIBODY; MALARIA VACCINE;

ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DELAYED HYPERSENSITIVITY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INOCULATION; MALARIA FALCIPARUM; NORMAL HUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SKIN BIOPSY; SKIN TEST; SPOROZOITE; T LYMPHOCYTE ACTIVATION; VOLUNTEER;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOGLOBULIN G; INTRADERMAL TESTS; MALARIA VACCINES; MALARIA, FALCIPARUM; MIDDLE AGED; PLASMODIUM FALCIPARUM; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 0037086689     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00037-3     Document Type: Article

References (44)

1. The need for assays predictive of protection in development of malarial blood stage vaccines
2. Malaria vaccines
3. Intrakutane reaktion als diagnose der malaria
4. Multitest CMI for standardized measurement of delayed cutaneous hypersensitivity
5. Delayed-type hypersensitivity skin tests are an independent predictor of human immunodeficiency virus disease progression
6. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: Long-term follow-up
7. Delayed-type hypersensitivity skin testing using third variable loop peptides identifies T lymphocyte epitopes in human immunodeficiency virus-infected persons
8. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria
9. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites
10. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine
11. Induction of protective polyclonal antibodie by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine
12. Protective immunity induced in squirrel monkeys with a multiple antigen construct against the circumsporozoite protein of Plasmodium vivax
13. Malaria vaccine: Immunization of mice with a synthetic T cell helper epitope alone leads to protective immunity
14. Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes
15. Immunogenicity of an alum-adsorbed synthetic multiple-antigen peptide based on B- and T-cell epitopes of the Plasmodium falciparum CS protein: Possible vaccine application
16. Immunogenicity of multiple antigen peptides (MAP) containing T and B cell epitopes of the repeat region of the P. falciparum circumsporozoite protein
17. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: Identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein
18. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes
19. Conserved repetitive epitope recognized by CD4+ clones from a malaria- immunized volunteer
20. Structural and immunological characterization of the vaccine adjuvant QS-21
21. Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, Osp B, and the saponin adjuvant QS21
22. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine
23. Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice
24. In vivo methods for study of allergy. Skin tests, techniques, and interpretation
25. Tuberculin reaction size measurement by the pen method compared to traditional palpation
26. Activation of antigen-specific suppressor T cells by the intravenous injection of soluble blood-stage malarial antigen
27. Cell-mediated immune responses to vaccine peptides derived from the circumsporozoite protein of Plasmodium falciparum
28. Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria
29. Immunogenicity of recombinant S. typhimurium expressing a hybrid antigen of Plasmodium falciparum
30. Delayed dermal hypersensitivity in rhesus monkeys (Macaca mulatta) immunized against Plasmodium knowlesi
31. Histoanalytical study of the cellular infiltrate in the tuberculin reaction
32. Contribution of human leukocyte antigens to the antibody response to Hepatitis B vaccination
33. CD4(+) T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17 kDa hepatocyte erythrocyte protein
34. Long-term efficacy and immune responses following immunization with the RTS, S malaria vaccine
35. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine
36. Immunosuppression in children with malaria
37. Cutaneous delayed-type hypersensitivity responsiveness in patients during and after Plasmodium falciparum and Plasmodium vivax infections
38. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells
39. Instability of tuberculin and Candida skin test reactivity in HIV-infected Ugandans. The Uganda-Case Western Reserve University Research Collaboration
40. Human immunodeficiency virus status and delayed-type hypersensitivity skin testing in Ugandan children
41. Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection
42. Cell-mediated immunity in patients with carcinoma: Correlation between clinical stage and immunocompetence
43. Host resistance in sepsis and trauma